Circumspectives: The promise of Ketamine

Neuropsychopharmacology

Volumn 40, Issue 2, 2015, Pages 257-258

  Carlezon, William A ^a   George, Tony P ^b  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; KETAMINE; SCOPOLAMINE; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; CLINICAL STUDY; DRUG INDUSTRY; EDITORIAL; HUMAN; PRIORITY JOURNAL; SCIENTIST; ANIMAL; MOOD DISORDERS;

ANIMALS; ANTIDEPRESSIVE AGENTS; HUMANS; KETAMINE; MOOD DISORDERS;

EID: 84926656798     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.270     Document Type: Editorial

References (6)

1. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475: 91-95.
2. Dranovsky A, Hen R (2006). Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 59: 1136-1143.
3. Furey ML, Drevets WC (2006). Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebocontrolled clinical trial. Arch Gen Psychiatry 63: 1121-1129.
4. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
5. Sanacora G, Schatzberg AF (2015). Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology (this issue).
6. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.